Alakeel Abdullah, Al Sheikh Afaf, Alraddadi Ali A, Alattas Khalid Mohammed, Aldayel Maha, Alajlan Mohammed Abdulaziz, Al-Haddab Mohammed, Almohideb Mohammad, Fatani Mohamed, Hamadah Issam R, Alharithy Ruaa, Binamer Yousef, Papp Kim, Elaraby Ahmed
Department of Dermatology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Division of Dermatology, Department of Medicine, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Clin Cosmet Investig Dermatol. 2022 Jul 26;15:1435-1445. doi: 10.2147/CCID.S357178. eCollection 2022.
Atopic dermatitis (AD) is a long-term, pruritic, recurrent, systemic, inflammatory skin disorder. In the Middle East region, the burden of AD is understudied, and there is a dearth of AD guideline documents for practitioners.
An expert panel meeting, encompassing 12 dermatologists from the Kingdom of Saudi Arabia (KSA), was congregated to develop evidence- and experience-based consensus recommendations for AD management, especially in adults in KSA. They completed a questionnaire with seven clinical statements, and a consensus was defined when the responses of ≥75% of participants coincided.
The expert recommendations were as follows: American Association of Dermatology guidelines are to be followed for defining AD; Eczema Area and Severity Index or SCORing atopic dermatitis index may be used to quantify the disease severity; Dermatology Life Quality Index may be used to determine the impact of AD on patients' quality of life; Atopic Dermatitis Control Tool may be used to assess long-term disease control in AD patients; and the European guidelines are to be followed for the management of AD. In AD patients who are inadequately controlled with topical or systemic therapies, the preferred systemic agent for use either alone or in combination with topical treatments is dupilumab, cyclosporine, methotrexate, phototherapy, or other available systemic treatments that may include mycophenolate mofetil or oral corticosteroids.
These expert recommendations assist physicians by providing a reference framework for optimal care of adult AD patients.
特应性皮炎（AD）是一种长期的、瘙痒性的、复发性的、全身性的炎症性皮肤病。在中东地区，对AD负担的研究不足，且缺乏供从业者参考的AD指南文件。
召集了一个由来自沙特阿拉伯王国（KSA）的12名皮肤科医生组成的专家小组会议，以制定基于证据和经验的AD管理共识建议，尤其是针对KSA的成年患者。他们完成了一份包含七条临床陈述的问卷，当≥75%的参与者回答一致时达成共识。
专家建议如下：定义AD应遵循美国皮肤科协会指南；可使用湿疹面积和严重程度指数或特应性皮炎评分指数来量化疾病严重程度；可使用皮肤病生活质量指数来确定AD对患者生活质量的影响；可使用特应性皮炎控制工具来评估AD患者的长期疾病控制情况；AD的管理应遵循欧洲指南。对于局部或全身治疗控制不佳的AD患者，单独使用或与局部治疗联合使用的首选全身药物是度普利尤单抗、环孢素、甲氨蝶呤、光疗或其他可用的全身治疗方法，其中可能包括霉酚酸酯或口服糖皮质激素。
这些专家建议为成人AD患者的最佳护理提供了参考框架，有助于医生。
